Astrazeneca Plc $AZN Stock Position Lowered by FNY Investment Advisers LLC

FNY Investment Advisers LLC decreased its position in Astrazeneca Plc (NYSE:AZN) by 97.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 200 shares of the company’s stock after selling 7,050 shares during the period. FNY Investment Advisers LLC’s holdings in Astrazeneca were worth $38,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Cooper Financial Group purchased a new stake in shares of Astrazeneca in the second quarter valued at $1,203,000. Assenagon Asset Management S.A. grew its holdings in shares of Astrazeneca by 45.5% during the second quarter. Assenagon Asset Management S.A. now owns 1,352,177 shares of the company’s stock valued at $256,049,000 after buying an additional 422,866 shares in the last quarter. 55 North Private Wealth LLC acquired a new position in Astrazeneca during the second quarter valued at $450,000. Thrive Wealth Management LLC acquired a new position in Astrazeneca during the second quarter valued at $429,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Astrazeneca in the 2nd quarter worth about $3,887,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Price Performance

NYSE AZN opened at $161.28 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $250.12 billion, a PE ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. The company has a 50 day moving average price of $176.34 and a two-hundred day moving average price of $187.12. Astrazeneca Plc has a 12-month low of $145.79 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. Astrazeneca’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.17 EPS. As a group, equities analysts predict that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Weiss Ratings cut shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, Bank of America reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.